The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: a retrospective clinical study and in vitro assessment of lipid-genes transcription

References

• An X, Tiwari AK, Sun Y, et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010;34:1255–1268.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Zabriskie MS, Eiring AM, et al. Pushing the limits of targeted therapy in chronic myeloid leukemia. Nat Rev Cancer. 2012;12:513–526.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc. 2015;90:1440–1454.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006;108:1835–1840.
   PubMed Web of Science ®Google Scholar
• Franceschino A, Tornaghi L, Benemacher V, et al. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. Haematologica. 2008;93:317–318.
   PubMed Web of Science ®Google Scholar
• Gologan R, Constantinescu G, Georgescu D, et al. Hypolipemiant besides antileukemic effect of imatinib mesylate. Leuk Res. 2009;33:1285–1287.
   PubMed Web of Science ®Google Scholar
• Gottardi M, Manzato E, Gherlinzoni F. Imatinib and hyperlipidemia. N Engl J Med. 2005;353:2722–2723.
   PubMed Web of Science ®Google Scholar
• Iurlo A, Orsi E, Cattaneo D, et al. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Oncotarget. 2015;6:33944–33951.
   PubMed Web of Science ®Google Scholar
• Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003;2:517–526.
   PubMed Web of Science ®Google Scholar
• Kesaniemi YA, Witztum JL, Steinbrecher UP. Receptor-mediated catabolism of low density lipoprotein in man. Quantitation using glucosylated low density lipoprotein. J Clin Invest. 1983;71:950–959.
   PubMed Web of Science ®Google Scholar
• Fujino T, Navaratnam N, Scott J. Human apolipoprotein B RNA editing deaminase gene (APOBEC1). Genomics. 1998;47:266–275.
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Klerkx AH, Stroes ES, et al. A review of CETP and its relation to atherosclerosis. J Lipid Res. 2004;45:1967–1974.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96:1070–1079.
   PubMed Web of Science ®Google Scholar
• Ashur-Fabian O, Har-Zahav A, Shaish A, et al. ApoB and apobec1, two genes key to lipid metabolism, are transcriptionally regulated by p53. Cell Cycle. 2010;9:3761–3770.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Blankenberg S, Landmesser U. The year in cardiology 2015: prevention. Eur Heart J. 2016;37:510–519.
   PubMed Web of Science ®Google Scholar
• Yang HQ, Qiu FQ, Jin KE, et al. High plasma levels of oxidatively modified low-density lipoproteins are associated with the suppressed expression of immunomodulatory molecules in patients with hematological malignancies. Exp Ther Med. 2015;9:2394–2400.
   PubMed Web of Science ®Google Scholar
• Glodkowska-Mrowka E, Mrowka P, Basak GW, et al. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib. Exp Hematol. 2014;42:439–447.
   PubMed Web of Science ®Google Scholar
• Chen R, Xiao W, Li D, et al. Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death. Med Oncol. 2011;28:528–531.
   PubMed Web of Science ®Google Scholar
• van Besien H, Sassano A, Altman JK, et al. Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Leuk Lymphoma. 2013;54:2601–2605.
   PubMed Web of Science ®Google Scholar
• Rea D, Mirault T, Cluzeau T, et al. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica. 2014;99:1197–1203.
   PubMed Web of Science ®Google Scholar
• Boucher P, Gotthardt M, Li WP, et al. LRP: role in vascular wall integrity and protection from atherosclerosis. Science. 2003;300:329–332.
   PubMed Web of Science ®Google Scholar
• Breccia M, Molica M, Alimena G. How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review. Leuk Res. 2014;38:1392–1398.
   PubMed Web of Science ®Google Scholar
• Teng B, Ishida B, Forte TM, et al. Effective lowering of plasma, LDL, and esterified cholesterol in LDL receptor-knockout mice by adenovirus-mediated gene delivery of ApoB mRNA editing enzyme (Apobec1). Arterioscler Thromb Vasc Biol. 1997;17:889–897.
   PubMed Web of Science ®Google Scholar
• Brown MS, Kovanen PT, Goldstein JL. Regulation of plasma cholesterol by lipoprotein receptors. Science. 1981;212:628–635.
   PubMed Web of Science ®Google Scholar
• Maksumova L, Ohnishi K, Muratkhodjaev F, et al. Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin. Leukemia. 2000;14:1444–1450.
   PubMed Web of Science ®Google Scholar
• Chen CW, Cheng HH. A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes. J Nutr. 2006;136:1472–1476.
   PubMed Web of Science ®Google Scholar
• Jurevics H, Hostettler J, Barrett C, et al. Diurnal and dietary-induced changes in cholesterol synthesis correlate with levels of mRNA for HMG-CoA reductase. J Lipid Res. 2000;41:1048–1054.
   PubMed Web of Science ®Google Scholar
• Plat J, Mensink RP. Effects of plant stanol esters on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase mRNA expression in mononuclear blood cells of healthy men and women. Faseb J. 2002;16:258–260.
   PubMed Web of Science ®Google Scholar
• Hinchcliff M, Huang CC, Ishida W, et al. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. Clin Exp Rheumatol. 2012;30:S86–S96.
   PubMed Web of Science ®Google Scholar
• Jiang XC, Masucci-Magoulas L, Mar J, et al. Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesteryl ester transfer protein. Mechanism to explain accumulation of lipoprotein B particles. J Biol Chem. 1993;268:27406–27412.
   PubMed Web of Science ®Google Scholar
• Ellis MH, Baraf L, Shaish A, et al. Alteration of lipids and the transcription of lipid-related genes in myelodysplastic syndromes via a TP53-related pathway. Exp Hematol. 2012;40:540–547.e1.
   PubMed Web of Science ®Google Scholar
• Law JC, Ritke MK, Yalowich JC, et al. Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res. 1993;17:1045–1050.
   PubMed Web of Science ®Google Scholar